CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE
Clinical safety rating: avoid
Positive evidence of fetus risks but benefits may outweigh risks in some cases
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
| Metabolism | Amitriptyline is metabolized primarily by CYP2C19, CYP2D6, and CYP3A4; chlordiazepoxide is metabolized by CYP3A4. |
| Excretion | Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%. |
| Half-life | Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment. |
| Protein binding | Chlordiazepoxide: 90-98% bound to albumin. Amitriptyline: 82-96% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Chlordiazepoxide: 0.3-1.0 L/kg (large distribution to tissues). Amitriptyline: 15-30 L/kg (extensive tissue binding, high Vd). |
| Bioavailability | Chlordiazepoxide: oral ~100% (well absorbed). Amitriptyline: oral 30-60% (first-pass metabolism). |
| Onset of Action | Oral: 30-60 minutes for anxiolytic/sedative effects; peak plasma levels 1-4 hours for both components. |
| Duration of Action | Chlordiazepoxide: 24-48 hours (due to active metabolites). Amitriptyline: 24 hours or longer (sedation may persist up to 48 hours). Clinical effects: anxiolytic/sedative 4-6 hours after single dose, but antidepressant effects delayed 2-4 weeks. |
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
| Dosage form | TABLET |
| Renal impairment | GFR ≥30 mL/min: no adjustment. GFR 15-29 mL/min: use with caution, reduce dose by 50%. GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for use in children under 12 years due to lack of safety data. For adolescents ≥12 years, dosing is similar to adult but start at lower dose (e.g., 1 capsule of 5 mg/12.5 mg 2-3 times daily). |
| Geriatric use | Initiate at 1 capsule (5 mg/12.5 mg) orally 2-3 times daily; increase cautiously. Maximum daily dose: 2 capsules (10 mg/25 mg) 3 times daily. Monitor for sedation, anticholinergic effects, and falls. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
CNS depressants including alcohol and opioids increase sedation risk Abrupt discontinuation can cause withdrawal symptoms.
| Breastfeeding | Both drugs are excreted into breast milk. Chlordiazepoxide M/P ratio approximately 0.5-1.0; amitriptyline M/P ratio approximately 0.8-1.5. Infant exposure is considered low to moderate. Monitor for sedation, poor feeding, and respiratory depression in the infant. The American Academy of Pediatrics considers amitriptyline as usually compatible with breastfeeding, while chlordiazepoxide use requires caution. |
| Teratogenic Risk | First trimester: Benzodiazepine exposure (chlordiazepoxide) may increase risk of oral clefts (pooled OR 1.5-2.0) based on limited data. Amitriptyline has shown mixed results; some studies suggest no significant increase in major malformations overall. Second and third trimesters: Benzodiazepines are associated with 'floppy infant syndrome' (hypotonia, respiratory depression, feeding difficulties) and withdrawal symptoms in neonates. Amitriptyline has no well-defined structural teratogenicity but may cause transient neonatal adaptation syndrome if used late in pregnancy. |
■ FDA Black Box Warning
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS - Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening and suicidality.
| Common Effects | alcohol withdrawal |
| Serious Effects |
["Concomitant use with MAOIs","Recent myocardial infarction","Hypersensitivity to either component","Angle-closure glaucoma (amitriptyline)","Concurrent use with linezolid or methylene blue"]
| Precautions | ["Suicidality risk","Serotonin syndrome","Cardiotoxicity (QT prolongation)","Sedation and psychomotor impairment","Avoid abrupt discontinuation"] |
| Food/Dietary | Avoid alcohol and grapefruit juice; grapefruit juice may increase amitriptyline levels. High-fat meals can delay absorption of chlordiazepoxide. Maintain adequate fluid intake to prevent constipation from anticholinergic effects. |
Loading safety data…
| Fetal Monitoring | Monitor for maternal sedation, ataxia, and dependence. In the neonate, observe for signs of withdrawal (irritability, hypertonia, seizures) and 'floppy infant syndrome' (hypotonia, poor suck) after in utero exposure. Consider fetal ultrasound for structural anomalies if first-trimester exposure. No specific routine fetal monitoring recommended beyond standard prenatal care. |
| Fertility Effects | Both drugs may cause menstrual irregularities (amitriptyline) and altered libido (benzodiazepines). Hyperprolactinemia has been reported with amitriptyline. In males, amitriptyline may cause erectile dysfunction. Limited data on direct effects on fertility; however, these effects are generally reversible upon discontinuation. |
| Clinical Pearls | Chlordiazepoxide/amitriptyline combines a benzodiazepine and a tricyclic antidepressant. The antidepressant component (amitriptyline) has significant anticholinergic effects; use cautiously in elderly patients, those with benign prostatic hyperplasia, or glaucoma. The benzodiazepine component (chlordiazepoxide) has dependence potential; limit to short-term use (2-4 weeks). Avoid co-administration with MAOIs or within 14 days of MAOI discontinuation. Monitor for serotonin syndrome when combined with other serotonergic drugs. Use lower starting doses in hepatic impairment due to reduced clearance. |
| Patient Advice | Do not abruptly stop this medication; taper under medical supervision to avoid withdrawal symptoms. · Avoid alcohol and other CNS depressants (e.g., opioids, sedatives) as they increase sedation and respiratory depression risk. · This medication may cause drowsiness; do not drive or operate heavy machinery until you know how it affects you. · Rise slowly from sitting or lying positions to minimize dizziness. · Report any signs of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness) immediately. · Take exactly as prescribed; do not increase dose or frequency without consulting your doctor. |